Latest Breaking News On - I mab daily - Page 1 : vimarsana.com

I-Mab (NASDAQ:IMAB) Shares Down 0 6%

I-Mab (NASDAQ:IMAB) Shares Down 0 6%
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Piper sandlerAcadian asset managementNeedham companyCompany profileConnor clark lunn investment management ltdDonaldl haganGet free reportAsset managementPension plan investment boardConnor clarkLunn investment managementI mab daily

I-Mab (NASDAQ:IMAB) Stock Price Down 0 6%

I-Mab (NASDAQ:IMAB) Stock Price Down 0 6%
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Piper sandlerConnor clark lunn investment management ltdNeedham companyCompany profileAcadian asset managementDonaldl haganGet free reportLunn investment managementAsset managementCanada pension plan investment boardI mab daily

Needham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)

I-Mab (NASDAQ:IMAB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They currently have a $6.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 231.49% from the stock’s previous […]

United statesPiper sandlerGoldman sachs group incNeedham companyCantor fitzgeraldBlackrock incAmerica corpJpmorgan chase coCompany profileVanguard group incGet free reportMab trading downSachs groupI mab dailyI mabNasdaq imab

Reviewing I-Mab (NASDAQ:IMAB) and Cerevel Therapeutics (NASDAQ:CERE)

I-Mab (NASDAQ:IMAB – Get Free Report) and Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 22.6% of I-Mab shares are […]

United kingdomUnited statesKalbe genexine biologicsAbbvie ireland unlimited companySinopharm group coJumpcan pharmaceutical groupCerevel therapeutics holdings incGet free reportCerevel therapeuticsGiveni mabCerevel therapeuticGenexine biologicsSinopharm groupTherapeutics holdingsI mab dailyI mab

Cantor Fitzgerald Reaffirms Overweight Rating for I-Mab (NASDAQ:IMAB)

Cantor Fitzgerald restated their overweight rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for I-Mab’s FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.14) EPS. Separately, Needham & Company LLC dropped their price target on shares of […]

Hong kongPanagora asset management incFund management hong kong coCantor fitzgeraldCitigroup incJpmorgan chase coCompany profileE fund management hong kong coNeedham companyAcadian asset managementFree reportFund management hong kongAsset managementPanagora asset managementGet free reportI mab daily